SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD

Review checklist: Nelson Mandela (HR-ML021)
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
- 11judgment calls in the dossier
- 2protocol deviations
- 1orders and referrals without results in the record
- 0evidence items to check (retrospective or sensitive claims, unconfirmed diagnoses)
Review status
| Review | Status | Reviewer | Date | Notes |
|---|
| schema validation | not_started | | | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | | | Awaiting clinician review; check the risk grouping, the choice of six months of androgen deprivation and conventional fractionation at 82, and the androgen deprivation monitoring. |
| provenance review | not_started | | | Recent-death rule: only what his doctors, his spokeswoman, his office, and he himself made public, with basic biographical facts from the Nelson Mandela Foundation. No statement or health fact is attributed to a relative or colleague. |
| safe messaging review | not_started | | | Imprisonment and tuberculosis are recorded as history only, factually; no behavioral-health diagnosis; death recorded without detail. |
Judgment calls (dossier editorial resolutions)
- Recent-death rule. Mandela died in 2013. The case uses only what his doctors, his spokeswoman, and his office made public in July and August 2001, his own announcement in 2002 that his doctors had cleared him, and basic biographical facts from the Nelson Mandela Foundation. His doctors and spokeswoman are not named in the record. No medical records, accounts by relatives or colleagues, or speculation about undisclosed conditions are used. The PSA value, MRI, biopsy pathology, Grade Group, stage, risk group, PSMA PET result, radiotherapy dose and technique, the leuprolide and bicalutamide regimen, every result, every examination finding, and the preventive care are synthetic. No sick visit is added. The recent-death review rule applies.
- Imprisonment and tuberculosis. His imprisonment, the prisons, and his release are recorded as history in the timeline, factually and without comment. The 1988 tuberculosis is recorded as documented past history and as a resolved history problem (Z86.11); the record adds no finding about his lungs beyond a normal examination and no symptoms. No source describes his tuberculosis treatment, so none is given.
- Earlier prostate operation. The Nelson Mandela Foundation and his urologist (as reported in The Globe and Mail) date the operation to 1985 and say part of the gland was removed for an enlarged gland causing a urinary blockage. Health24 gives 1990 and says most of the gland was removed. The record uses 1985 and “part of the gland”, does not name the type of operation, and uses the resection defect only as a synthetic MRI finding and as a factor in the treatment choice.
- Index age and dates. The modern episode presents Mandela at 82, after the PSA rise and before radiotherapy. The synthetic date of birth is July 18, 1943 (shift 25 years). The PSA rise is placed in November 2025 (true frame November 2000, the month the news reports give). The MRI on January 20 and the biopsy on February 10, 2026 map to January and February 2001; their true dates were not made public, and they are placed between the PSA rise and the start of hormone therapy, as the public account requires. The index visit on March 10, 2026 maps to March 10, 2001. The consultation and chronic-care visit on April 14, the annual wellness visit on June 9, the chronic-care visits on July 14 and October 27, 2026 map to the same days of 2001. Radiotherapy starts on July 24, 2026, which maps to July 24, 2001, the day the news reports say his radiotherapy began. He turns 83 on July 18, between the third visit and radiotherapy, which matches the reports that called him 83 that week. Past medical history holds only the 1985 operation, the 1988 tuberculosis, and the November 2000 PSA rise.
- Synthetic clinical picture. The public account gives a slight PSA rise on monitoring, a biopsy showing microscopic cancer that was not of a high grade, hormonal treatment with anti-androgens for a while, and about seven weeks of curative radiotherapy limited to the prostate, with no surgery or chemotherapy. The synthetic picture is chosen to fit and to teach current practice: PSA 6.4 ng/mL, Grade Group 3 in 3 of 14 cores, cT1c N0 M0, NCCN unfavorable intermediate risk, for which radiotherapy with four to six months of androgen deprivation is the standard option. Conventional fractionation, 74 Gy in 37 fractions over about seven and a half weeks, is used so that the course is close to the documented seven weeks; the consultant records moderate hypofractionation as an equivalent choice. The anti-androgen in the public account appears as four weeks of bicalutamide to cover the leuprolide flare. Results are kept normal or mild (vitamin D 26 ng/mL, femoral neck T-score -1.4, PHQ-9 4) so that nothing reads as a claim about his undisclosed health.
- The decision in the record and the public account. His office said in August 2001 that a review of the options by physicians, a radiotherapist, and urologists led to the decision to continue radiation. In the synthetic record the shared decision is made at the radiation oncology consultation before treatment, which is current practice. The record does not reproduce or comment on the real review.
- 2002 announcement. His announcement that his doctors had cleared him is recorded as a claim and in the timeline. It falls after the end of the episode, so the record states nothing about later PSA results.
- Annual wellness visit. A subsequent Medicare annual wellness visit (age 82, so `annual_wellness_subsequent`) was added on June 9, 2026 (true frame June 9, 2001), seven weeks into androgen deprivation. Judgment calls: (1) never smoker and no alcohol are synthetic, not drawn from a source; (2) colorectal screening and a statin for primary prevention were discussed and not recommended at his age; (3) advance care planning names an unnamed health care agent and records only general priorities; (4) a missed whispered-voice test on the left leads to audiology, which finds mild high-frequency loss, a synthetic, age-typical finding.
- Focused visits. The three chronic-care follow-ups (five weeks, four months, and seven and a half months after the first visit) are documented as focused visits on the CMID prostate cancer monograph, the NCCN guideline, and the AUA/ASTRO 2022 guideline. Each lists every item the protocol calls for at that point, with its interval and status. The first is the same day as the radiation oncology consultation and the DXA scan. One protocol deviation is recorded instead of an invented result: bowel function was not asked about at the visit before radiotherapy. The wellness visit five weeks earlier had recorded regular bowel movements, he confirmed this afterwards, so no harm is judged to have resulted; the question was added to the pre-radiotherapy checklist. Synthetic findings introduced: grade 1 urinary frequency in the fourth week of radiotherapy treated with tamsulosin by radiation oncology, and grade 1 looser stools at the end of radiotherapy, both improving. Sexual function is recorded only as reviewed, with no specific finding, to avoid detail about his private life.
- Consultation. The radiation oncology referral and the consultation by Pieter van Zyl, MD (a fictional consultant), on the day of the first focused visit, are S. The consultant answers the five referral questions with what the record shows happened afterwards: the unfavorable intermediate risk group with staging complete; observation discussed, and surgery, brachytherapy, and active surveillance not advised; six months of androgen deprivation (bicalutamide for four weeks, leuprolide twice, twelve weeks apart) with radiotherapy starting about three months after the first injection; 74 Gy in 37 fractions with fiducial guidance; tamsulosin if urinary symptoms develop; and the monitoring and PSA surveillance plan. The examination is consistent with Dr. Mokoena’s same-day note.
- Not used. His later illnesses and hospital admissions, eye problems, the reports of the illnesses of other public figures in the news coverage, and a CBS News page whose dateline (1998) conflicts with its content were not used. His height is not recorded in a fetched source; the 183 cm in the record is synthetic.
Protocol deviations
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
| Visit | Measure | Interval | What happened |
|---|
2026-07-14 Progress note 04 (C-CDA) | Bowel function before radiotherapy | Baseline before radiotherapy, then every visit after it | Not asked today, a deviation from the protocol; the visit was taken up by the androgen deprivation results and the radiotherapy plan. To be checked at the next visit |
2026-10-27 Progress note 05 (C-CDA) | Bowel baseline missed before radiotherapy | Baseline before radiotherapy | Not asked at the visit before radiotherapy, a deviation from the protocol. The wellness visit five weeks before that had recorded regular, formed stools once a day, and he confirms this today, so a baseline was available and no harm resulted. The bowel question is now on the pre-radiotherapy checklist |
Orders and referrals without results in the record
| Visit | Type | Item | Status | Detail |
|---|
2026-06-09 Progress note 03 (C-CDA) | Prevention | Hearing | Referred | Whispered-voice test missed on the left; audiology arranged |
Evidence to check
Retrospective claims (R)
None.
Sensitive claims
None.
Diagnoses not confirmed
None.
Notes to read
Every note in the record, with its type. All clinical content is synthetic.
Abnormal results
| Date | Result | Value | Flag |
|---|
| 2026-03-10 | PSA | 6.4 ng/mL (high) | High |
| 2026-03-10 | 25-hydroxyvitamin D | 26 ng/mL (low) | Low |
| 2026-04-14 | Femoral neck T-score (DXA) | -1.4 (low) | Low |
| 2026-07-14 | Total testosterone | 18 ng/dL (low) | Low |
| 2026-10-27 | Total testosterone | 38 ng/dL (low) | Low |